Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies

Clinical Infectious Diseases

Volumn 35, Issue 12, 2002, Pages 1463-1468

  Feld, Ronald ^a   Paesmans, Marianne ^b   Freifeld, Alison G ^c   Klastersky, Jean ^b   Pizzo, Philip A ^e   Rolston, Kenneth V I ^f   Rubenstein, Edward ^f   Talcott, James A ^d   Walsh, Thomas J ^g  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JULES BORDET INSTITUTE   (Belgium)

^c NEBRASKA MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER THERAPY; FEBRILE NEUTROPENIA; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; METHODOLOGY; OUTCOMES RESEARCH; OUTPATIENT CARE; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT INDICATION; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEVER; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; NEUTROPENIA; OUTPATIENTS; PATIENT SELECTION;

EID: 0037115343     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344650     Document Type: Article

References (18)

1. Peter JL, Weir L. Reporting the results of randomized trials of empiric antibiotics in febrile neutroponic patients - A critical survey. J Clin Oncol 1986; 4:346-52.
2. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981; 2:31-49.
3. Immunocompromised Host Society. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: Report of a consensus panel. J Infect Dis 1990; 161:397-401.
4. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15(Suppl 1):S206-15.
5. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995;31A:2013-22.
6. Feld R. Organization of clinical trials: Problems, controversies, definitions and methodology related to infections in neutropenic patients. In: Schimpff SC, Klastersky J, eds. Infectious Complications in Bone Marrow Transplantation. Berlin: Springer-Verlag, 1993:249-56.
7. Feld R. Methodology for clinical trials in cancer patients with febrile neutropenia: Do we have a consensus? Support Care Cancer 1998; 6:423-4.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-16.
9. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305-11.
10. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8.
11. Talcott JA, Finberg RW. Fever and neutropenia - How to use a new treatment strategy. N Engl J Med 1999; 341:362-3.
12. Rubenstein EB, Rolston KVI, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71:3640-6.
13. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130:515-24.
14. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988; 148:2561-8.
15. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk-index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
16. Talcott JA, Seigel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316-22.
17. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012-9.
18. Pizzo PA, Robichaud KJ, Edwards BK, Schumacher C, Kramer BS, Johnson A. Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial. J Pediatr 1983; 102:125-33.